The Treatment of Hypertension in Patients with Erectile Dysfunction

Current Medical Research and Opinion

Volumn 16, Issue sup1, 2000, Pages s31-s36

  Mikhailidis, Dimitri P ^b   Khan, Masood A ^a   Milionis, Haralampos J ^b   Morgan, Robert J ^a  

^a Department of Urology ^*  (United States)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Beta blockers; Diuretics; Doxazosin; Erectile dysfunction; Hypertension

Indexed keywords

ACEBUTOLOL; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHLORTALIDONE; DOXAZOSIN; ENALAPRIL; PROSTAGLANDIN E1; SILDENAFIL; THIAZIDE DIURETIC AGENT;

ARTICLE; ATHEROSCLEROSIS; CLINICAL TRIAL; DIABETES MELLITUS; DRUG CHOICE; DRUG POTENTIATION; ERECTILE DYSFUNCTION; GLUCOSE INTOLERANCE; HUMAN; HYPERTENSION; INCIDENCE; INSULIN RESISTANCE; INSULIN SENSITIVITY; MICTURITION; PREVALENCE; PROSTATE HYPERTROPHY;

ANTIHYPERTENSIVE AGENTS; DIABETES COMPLICATIONS; DOXAZOSIN; HUMANS; HYPERTENSION; IMPOTENCE; MALE; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES;

EID: 0033278342     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/0300799009117037     Document Type: Article

References (30)

1. Jeremy JY, Mikhailidis DP (1998). Cigarette smoking and erectile dysfunction. J. Roy. Soc. Health, 118, 151 – 155.
2. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB (1994). Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J. Urol., 151, 54 – 61.
3. Chiu AVV, Chen MT, Chang LS, Chang MS (1991). Penile brachial index in impotent patients with coronary artery disease. Eur. Urol., 19, 213 – 216.
4. Grimm RH Jr, Grandis GA, Prineas RJ, et al. for the TOMHS Research Group (1997). Long-term effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive men and women. Treatment of Mild Hypertension Study (TOMHS). Hypertension, 29, 8 – 14.
5. Kaplan SA, Reis RB, Kohn IJ, Shabsigh R, Te AE (1998). Combination therapy using oral alpha-blockers and intracavernosal injection in men with erectile dysfunction. Urology, 52, 739 – 743.
6. Lecerof H, Bornmyr S, Lilja B, De Pedis G, Hulthen UL (1990). Acute effects of doxazosin and atenolol on smoking-induced peripheral vasoconstriction in hypertensive habitual smokers. J. Hypertens., 8 (Suppl.), S29 – S33.
7. Muller SC, el-Damanhoury H, Ruth J, Lue TF (1991). Hypertension and impotence. Eur. Urol., 19, 29 – 34.
8. Jensen J, Lendorf A, Stimpel H, Frost J, Ibsen H, Rosenkilde P (1999). The prevalence and etiology of impotence in 101 male hypertensive outpatients. Am. J. Hypertens., 12, 271 – 275.
9. Webb DJ, Freestone S, Allen MJ, Muirhead GJ (1999). Sildenafil citrate and blood-pressure-lowering drugs: results of drug interaction studies with an organic nitrate and a calcium antagonist. Am. J. Cardiol., 83 (5A), 21C – 28C.
10. Hansson L, Zanchetti A, Carruthers SG, et al. for the HOT Study Group (1998). Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the patients with hypertension optimal treatment (HOT) randomised trial. Lancet, 351, 1755– 1762.
11. UK prospective Diabetes Study Group (1998). Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Br. Med. J., 317, 703 – 713.
12. Lithell H (1995). Metabolic aspects of the treatment of hypertension. J. Hypertens., 13, (Suppl. 2), S77 – S80.
13. Shieh S-M, Sheu WH-H, Shen D-C, Fuh MM-T, Chen Y-DI, Reaven GM (1992). Glucose, insulin, and lipid metabolism in doxazosin-treated patients with hypertension. Am. J. Hypertens., 5, 827 – 831.
14. Maatman TJ, Montague DK, Martin LM (1987). Erectile dysfunction in patients with diabetes mellitus. Urology, 29, 589 – 592.
15. Cabo L, Davis PA, Cantaro S, et al. (1998). Effect of doxazosin in mild to moderate hypertensive patients with insulin-dependent diabetes mellitus. Acta Diabetol., 35, 96 – 100.
16. Shionoiri H, Ashino K, Yamanaka K, Shindo K, Hiroto S, Arita T (1997). Effect of doxazosin therapy on glucose tolerance and lipid metabolism in hypertensive patients with impaired glucose tolerance. Clin. Ther., 19, 527 – 536.
17. Gerdts E, Svarstad E, Aanderud S, Myking OL, Lund-Johanson P. Omvik P (1998). Factors influencing reduction in blood pressure and left ventricular mass in hypertensive type-1 diabetic patients using captopril or doxazosin for 6 months. Am. J. Hypertens., 11, 1178 – 1187.
18. Giordano M, Sanders LR, Castellino P., Canessa ML, DeFronzo RA (1996). Effect of alpha-adrenergic blockers, ACE inhibitors, and calcium channel antagonists on renal function in hypertensive non-insulin-dependent diabetic patients. Nephron, 72, 447 – 453.
19. Papadakis JA, Ganotakis ES, Jagroop IA, Mikhailidis DP, Winder AF (1999). Effect of hypertension, and its treatment, on lipid, lipoprotein (a), fibrinogen and bilirubin levels in patients referred for dyslipidaemia. Am. J. Hypertens., 12, 673 – 681.
20. Hedner T, Sun X (1997). Measures of endo-thelial function as an endpoint in hypertension? Blood Pressure, Suppl., 2, 58 – 66.
21. Khan MA, Thompson CS, Sullivan ME, et al. (1998). Endothelin and erectile dysfunction: a target for pharmacological intervention? Exp. Opin. Invest. Drugs, 7, 1759– 1767.
22. Sullivan ME, Thompson CS, Dashwood MR, et al. (1999). Nitric oxide and penile erection: is erectile dysfunction another manifestation of vascular disease. Cardiovase. Res., 43, 658 – 665.
23. Garraway WM, Collins GN, Lee RJ (1991). High prevalence of benign prostatic hypertrophy in the community. Lancet, 338, 469 – 471.
24. Hammarsten J (1998). A new hypothesis for the aetiology of benign prostatic hyperplasia. Urol. News, 2, 11 – 14.
25. Namasivayam S, Minhas S, Brooke J, Joyce AD, Prescott S, Eardley I (1998). The evaluation of sexual function in men presenting with symptomatic benign prostatic hyperplasia. Br. J. Urol., 82, 842 – 846.
26. Grimm RH, Flack JM, Grandits GA, et al. for the Treatment of Mild Hypertension Study (TOMHS) Research Group (1996). Long-term effects on plasma lipids of diet and drugs to treat hypertension. J. Am. Med. Assoc., 275, 1549 – 1556.
27. Levy D, Walmsley P, Levenstein M (1996). Principal results of the Hypertension and Lipid Trial (HALT): A multicenter study of doxazosin in patients with hypertension. Am. Heart J., 131, 966 – 973.
28. Zehetgruber M, Christ G, Gabriel H, et al. (1998). Effect of antihypertensive treatment with doxazosin on insulin sensitivity and fibrinolytic parameters. Thromb. Haemost., 79, 378 – 382.
29. Alarayyed NA, Cooper MB, Prichard BNC, Betteridge DJ, Smith CCT (1997). In vitro adrenaline and collagen-induced mobilization of platelet calcium and its inhibition by naftopidil, doxazosin and nifedipine. Br. J. Clin. Pharmacol., 43, 415 – 420.
30. British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, British Diabetic Association. Prepared by Wood D, Durrington P, Poulter N, McInnes G, Rees A, Wray Ron behalf of the Societies (1998). Joint British recommendations on prevention of coronary heart disease in clinical practice. Heart, 80 (Suppl 2), Si – S29.